Last reviewed · How we verify
NCT05166304
Rebamipide in Patients With Active Rheumatoid Arthritis
Phase 1, PHASE2 trial testing Rebamipide in Rheumatoid Arthritis in 60 participants. Completed in 1 September 2025.
1 August 2025
Quick facts
| Lead sponsor | October 6 University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 January 2024 |
| Primary completion | 1 August 2025 |
| Estimated completion | 1 September 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Rebamipide — full drug profile →
- Placebo
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Sponsor
October 6 University
Who can join
Adults 18 to 60, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Although the aetiology of RA remains to be fully elucidated, interleukin (IL)-17 are believed to play a critical role in the pathogenesis of RA. Rebamipide is an antiulcer drug that protects gastric epithelial cells,improves gastric defense mechanisms by increasing gastric mucus. Rebamipide inhibited interleukin (IL)-17, also it inhibits IL-1β-induced RASF proliferation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05166304
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rebamipide
Trials testing the same drug.
- NCT04885751 — Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy · Phase 4 · unknown
- NCT04649697 — Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumato · Phase 3 · unknown
- NCT04550858 — h.Pylori Ttt With Rebamipide · unknown
- NCT03608761 — Comparison Between Rebamipide 2% Versus Autologous Serum · Phase 4 · completed
- NCT02243618 — The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection- · NA · completed
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other October 6 University trials
Trials by the same sponsor.
- NCT07235072 — Passive Fit and Time Efficiency in All On-X Implants Protocols Using Photogrammetry, Splinted Scan Bodies, and Conventio · NA · not yet recruiting
- NCT07403851 — Effect of Scanning Technology on the Accuracy of Digitally Customized Intraradicular Attachments · NA · not yet recruiting
- NCT07305792 — High Tone Power Therapy on Lumbosacral Radiculopathy Patients · NA · completed
- NCT07132736 — Impact of Underwater Exercise Versus Regular Aerobic Exercise on Quality of Life and Power of Muscle · NA · recruiting
- NCT07350655 — Efficacy of Virtual Reality-based Training in Patients With Chronic Non-specific Low Back Pain · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05166304 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by October 6 University
- Last refreshed: 20 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05166304.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing